Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Stephens

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Clinics in Liver Disease|November 23, 2019
Genetic Predisposition to Drug-Induced Liver InjuryCamilla Stephens, Raúl J Andrade
Expert Opinion on Drug Metabolism & Toxicology|November 23, 2020
Genetic risk factors in the development of idiosyncratic drug-induced liver injuryCamilla Stephens, M Isabel Lucena, Raúl J Andrade
Frontiers in Genetics|November 20, 2012
Genetic variations in drug-induced liver injury (DILI): resolving the puzzleCamilla Stephens, M Isabel Lucena, Raúl J Andrade
Current Opinion in Allergy and Clinical Immunology|June 11, 2014
Mechanisms of drug-induced liver injuryCamilla Stephens, Raúl J Andrade, M Isabel Lucena
International Journal of Molecular Sciences|May 18, 2016
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryAida Ortega-Alonso, Camilla Stephens, M Isabel Lucena, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2020
Systematic review: ibuprofen-induced liver injuryMiguel E Zoubek, María Isabel Lucena, Raúl J Andrade, et al.
The Lancet. Gastroenterology & Hepatology|August 21, 2020
Drug-induced liver injury in older peopleM Isabel Lucena, Judith Sanabria, Miren García-Cortes, et al.
Gastroenterology|December 3, 2014
Reply: To PMID 24704526Mercedes Robles-Diaz, Neil Kaplowitz, Camilla Stephens, et al.
FEMS Microbiology Letters|January 26, 2005
The mode of action of the plant antimicrobial peptide MiAMP1 differs from that of its structural homologue, the yeast killer toxin WmKTCamilla Stephens, Kemal Kazan, Ken C Goulter, et al.
Gastroenterology|December 24, 2014
Reply: To PMID 24704526Mercedes Robles-Diaz, Neil Kaplowitz, Camilla Stephens, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Clinics in Liver Disease|November 23, 2019
Genetic Predisposition to Drug-Induced Liver InjuryCamilla Stephens, Raúl J Andrade
Expert Opinion on Drug Metabolism & Toxicology|November 23, 2020
Genetic risk factors in the development of idiosyncratic drug-induced liver injuryCamilla Stephens, M Isabel Lucena, Raúl J Andrade
Frontiers in Genetics|November 20, 2012
Genetic variations in drug-induced liver injury (DILI): resolving the puzzleCamilla Stephens, M Isabel Lucena, Raúl J Andrade
Current Opinion in Allergy and Clinical Immunology|June 11, 2014
Mechanisms of drug-induced liver injuryCamilla Stephens, Raúl J Andrade, M Isabel Lucena
International Journal of Molecular Sciences|May 18, 2016
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryAida Ortega-Alonso, Camilla Stephens, M Isabel Lucena, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2020
Systematic review: ibuprofen-induced liver injuryMiguel E Zoubek, María Isabel Lucena, Raúl J Andrade, et al.
The Lancet. Gastroenterology & Hepatology|August 21, 2020
Drug-induced liver injury in older peopleM Isabel Lucena, Judith Sanabria, Miren García-Cortes, et al.
Gastroenterology|December 3, 2014
Reply: To PMID 24704526Mercedes Robles-Diaz, Neil Kaplowitz, Camilla Stephens, et al.
FEMS Microbiology Letters|January 26, 2005
The mode of action of the plant antimicrobial peptide MiAMP1 differs from that of its structural homologue, the yeast killer toxin WmKTCamilla Stephens, Kemal Kazan, Ken C Goulter, et al.
Gastroenterology|December 24, 2014
Reply: To PMID 24704526Mercedes Robles-Diaz, Neil Kaplowitz, Camilla Stephens, et al.
Pageof 6